Biogen Strikes Up To $2B Deal For Parkinson's Drug Collab
Biogen will buy a stake in fellow pharmaceutical company Denali as part of a collaboration on a potential treatment for Parkinson's disease, in a transaction worth up to $2 billion, the...To view the full article, register now.
Already a subscriber? Click here to view full article